Zwahlen Marcel, Gerber Susan, Bersinger Nick A
Division of Epidemiology and Biostatistics, Department of Social and Preventive Medicine, University of Berne, Berne, Switzerland.
Gynecol Obstet Invest. 2007;63(1):15-21. doi: 10.1159/000094672. Epub 2006 Jul 20.
BACKGROUND/AIM: Parallel investigation, in a matched case-control study, of the association of different first-trimester markers with the risk of subsequent pre-eclampsia (PE).
The levels of different first trimester serum markers and fetal nuchal translucency thickness were compared between 52 cases of PE and 104 control women by non-parametric two-group comparisons and by calculating matched odds ratios.
In univariable analysis increased concentrations of inhibin A and activin A were associated with subsequent PE (p < 0.02). Multivariable conditional logistic regression models revealed an association between increased risk of PE and increased inhibin A and translucency thickness and respectively reduced pregnancy-associated plasma protein A (PAPP-A) and placental lactogen . However, these associations varied with the gestational age at sample collection. For blood samples taken in pregnancy weeks 12 and 13 only, increased levels of activin A, inhibin A and nuchal translucency thickness, and lower levels of placenta growth factor and PAPP-A were associated with an increased risk of PE.
Members of the inhibin family and to some extent PAPP-A and placental growth factor are superior to other serum markers, and the predictive value of these depends on the gestational age at blood sampling. The availability of a single, early pregnancy 'miracle' serum marker for PE risk assessment seems unlikely in the near future.
背景/目的:在一项匹配病例对照研究中,对孕早期不同标志物与子痫前期(PE)风险之间的关联进行平行调查。
通过非参数两组比较和计算匹配比值比,比较了52例PE患者和104例对照女性孕早期不同血清标志物水平及胎儿颈部透明带厚度。
单变量分析中,抑制素A和激活素A浓度升高与随后发生的PE相关(p<0.02)。多变量条件逻辑回归模型显示,PE风险增加与抑制素A升高、透明带厚度增加以及妊娠相关血浆蛋白A(PAPP-A)和胎盘催乳素水平降低分别相关。然而,这些关联随样本采集时的孕周而变化。仅在妊娠第12周和第13周采集的血样中,激活素A、抑制素A水平升高、颈部透明带厚度增加以及胎盘生长因子和PAPP-A水平降低与PE风险增加相关。
抑制素家族成员以及在一定程度上PAPP-A和胎盘生长因子优于其他血清标志物,且这些标志物的预测价值取决于采血时的孕周。近期似乎不太可能有单一的孕早期“神奇”血清标志物可用于PE风险评估。